SS Innovations Launches Innovative Robotic Cardiac Surgery Program in India

SS Innovations International, Inc. (OTC: SSII) has announced the launch of an innovative robotic cardiac surgery program in India utilizing its flagship SSi Mantra surgical robotic system.

The company’s cardiac program aims to revive and invigorate the field of robotic coronary artery bypass and intracardiac surgery in India, and to train surgeons throughout the country in these procedures using the SSi Mantra.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, said, “Today more than 95% of patients are still being operated on in a maximally invasive approach globally, which means the splitting of the sternum is required to gain access to the heart. This results in greater blood loss, increased risk of wound infection with longer recoveries for the patient. Every patient should have access to gold standard surgical care, and we believe that our cost-effective surgical robotic system is a key part of the solution.”


In September 2023, Dr. Srivastava, a world-leading cardiac surgeon, performed the world’s first beating heart robotic cardiac bypass surgery using the SSi Mantra. The Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) is one of the most complex surgical approaches in cardiac surgery and a minimally invasive procedure performed on a beating heart, through tiny ports, in a closed chest, without the need for a cardiopulmonary bypass machine.

Dr. Srivastava has completed more than 1,400 robotic cardiothoracic surgical procedures, including 750 TECAB cases.

The SSi Mantra Surgical Robotic System is the first surgical system to be made in India, and one of the only systems in the world to be distinctly cost-effective with broad-spectrum surgical applications, including cardiac surgery.

More than 20 robotic cardiac surgeries have been successfully performed using SS Innovations’ surgical robotic system in India, to date.

SS Innovations expects to secure regulatory approvals in the United States and Europe in 2024 and 2025. 

About SS Innovations

SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at or LinkedIn for updates.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

About the Author

SS Innovations Launches Innovative Robotic Cardiac Surgery Program in India

Editor Prism MarketView